Abstract: This disclosure relates to a system and method to implement a performance test to help evaluate a patient's neurological and cognitive function. The performance test can be executed by the patient autonomously using a portable computing device, such as a tablet computer or smart phone. The portable computing device can be programmed to execute a set of modules configured to assess motor and cognitive performance, such as a manual function test module, a cognitive processing speed test module, and a movement assessment test module. The set of modules can also include a collection module to aggregate test data from the manual function test module, the cognitive processing speed test module, and the movement assessment test module.

Abstract: This disclosure relates to a system and method to implement a performance test to help evaluate a patient's neurological and cognitive function. The performance test can be executed by the patient autonomously using a portable computing device, such as a tablet computer or smart phone. The portable computing device can be programmed to execute a set of modules configured to assess motor and cognitive performance, such as a manual function test module, a cognitive processing speed test module, and a movement assessment test module. The set of modules can also include a collection module to aggregate test data from the manual function test module, the cognitive processing speed test module, and the movement assessment test module.

Abstract: This disclosure relates to a system and method to implement a performance test to help evaluate a patient's neurological and cognitive function. The performance test can be executed by the patient autonomously using a portable computing device, such as a tablet computer or smart phone. The portable computing device can be programmed to execute a set of modules configured to assess motor and cognitive performance, such as a manual function test module, a cognitive processing speed test module, and a movement assessment test module. The set of modules can also include a collection module to aggregate test data from the manual function test module, the cognitive processing speed test module, and the movement assessment test module.

Abstract: This disclosure relates to a system and method to implement a performance test to help evaluate a patient's neurological and cognitive function. The performance test can be executed by the patient autonomously using a portable computing device, such as a tablet computer or smart phone. The portable computing device can be programmed to execute a set of modules configured to assess motor and cognitive performance, such as a manual function test module, a cognitive processing speed test module, and a movement assessment test module. The set of modules can also include a collection module to aggregate test data from the manual function test module, the cognitive processing speed test module, and the movement assessment test module.

Abstract: A method is provided for determining the efficacy of interferon-beta (IFN-?) therapy in a subject with multiple sclerosis. One step of the method can include obtaining a biological sample from the subject. After obtaining the biological sample, the expression level of at least one interferon-regulated gene (IRG) and/or variant thereof can be determined. Increased or decreased expression of the at least one IRG and/or variant thereof as compared to a control may indicate that the subject will respond poorly to IFN-? therapy.

Abstract: A method of analyzing medical image data to measure brain atrophy and determine the severity and progression of multiple sclerosis or other condition which leads to neurodegeneration or axonal damage is provided. Magnetic resonance image data representing a brain of a subject is provided and a brain surface contour is automatically identified by separating the brain from other connected structures in the image data. A total volume within the brain surface contour is calculated. A brain volume is then determined within the surface contour which excludes fluid filled regions and accounts for partial volume effects. The brain volume is then normalized by the total contour volume which generates a brain parenchymal fraction. The brain parenchymal fraction serves as a reliable measurement of brain atrophy and assists in determining the severity and progression of multiple sclerosis or other condition which leads to neurodegeneration or axonal damage.

Abstract: Multiple sclerosis (MS) is diagnosed by determining with a quantitative immunoassay the quantity of free kappa light chains in the cerebrospinal fluid of a patient. The immunoassay is preferably a radioimmunoassay. In carrying out the immunoassay, the free kappa light chains are combined with antiserum specific thereto. This method of diagnosing MS has high sensitivity in distinguishing between normal patients and patients affected with MS.